Systemic Juvenile Idiopathic Arthritis and Secondary Macrophage Activation Syndrome in Latvia from 2009 to 2020 : A Nationwide Retrospective Study

Simple item page
dc.contributor.authorLukjanoviča, Kristīne
dc.contributor.authorŠlēziņa, Ieva
dc.contributor.authorDāvidsone, Zane
dc.contributor.authorŠantere, Ruta
dc.contributor.authorBudarina, Kristīna
dc.contributor.authorStaņēviča, Valda
dc.contributor.institutionResidency Unit
dc.contributor.institutionRīga Stradiņš University
dc.contributor.institutionDepartment of Paediatrics
dc.date.accessioned2023-05-03T08:50:01Z
dc.date.available2023-05-03T08:50:01Z
dc.date.issued2023-04-20
dc.descriptionZane Davidsone is a representative of European Reference Network on Connective Tissue and Musculoskeletal Disease-ERN-ReCONNET.
dc.description.abstractBackground and Objectives: Systemic juvenile idiopathic arthritis (sJIA) is a distinctive JIA subtype with mostly nonspecific systemic clinical features, which can be a diagnostic challenge. This study aimed to analyze our experience with sJIA in Latvia for twelve years: assessing clinical and epidemiological characteristics, the efficacy of therapy, and disease outcomes, including the development of macrophage activation syndrome (MAS). Materials and methods: This is a descriptive study in which we conducted a retrospective case review of all patients with sJIA diagnosis admitted to the only pediatric tertiary centre in Latvia during the period 2009-2020. Results: sJIA was diagnosed in 35 patients with a mean annual incidence rate of 0.85 patients per 100,000 children. Major clinical signs at the first visit were: fever, rash, arthritis, and lymphadenopathy. Almost half of the patients, 48.5%, had a monocyclic disease course, and only 20% of patients had persistent disease. MAS developed in 28.6% of patients. Biological therapy was administered to 48.6% of patients, mostly by tocilizumab, which induced remission in 75% after one year, and in 81.2% after two years without any serious therapy-related complications. In our study, none of the patients had interstitial lung disease, drug reaction with eosinophilia and systemic symptoms (DRESS)-like syndrome, or fatal disease. Conclusions: The incidence and clinical characteristics of sJIA correlate with the literature findings, although MAS was more common than described in other studies. There is a tendency for the persistent disease to decrease with the use of biological therapy. Tocilizumab is an efficient choice of treatment with a good safety profile.en
dc.description.statusPeer reviewed
dc.format.extent309191
dc.identifier.citationLukjanoviča, K, Šlēziņa, I, Dāvidsone, Z, Šantere, R, Budarina, K & Staņēviča, V 2023, 'Systemic Juvenile Idiopathic Arthritis and Secondary Macrophage Activation Syndrome in Latvia from 2009 to 2020 : A Nationwide Retrospective Study', Medicina (Kaunas, Lithuania), vol. 59, no. 4, 798. https://doi.org/10.3390/medicina59040798
dc.identifier.doi10.3390/medicina59040798
dc.identifier.issn1010-660X
dc.identifier.otherPubMedCentral: PMC10144400
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/11864
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85156178116&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofMedicina (Kaunas, Lithuania)
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectjuvenile arthritis
dc.subjectsystemic juvenile idiopathic arthritis
dc.subjectsJIA
dc.subjectstill’s disease
dc.subjectmacrophage activation syndrome;
dc.subjectMAS
dc.subjecttocilizumab
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.titleSystemic Juvenile Idiopathic Arthritis and Secondary Macrophage Activation Syndrome in Latvia from 2009 to 2020 : A Nationwide Retrospective Studyen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Systemic_Juvenile_Idiopathic_Arthritis.pdf
Size:
301.94 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure